WANBURY
Back to Balance Sheet
|
WANBURY Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹173 Cr | ₹99 Cr | ₹11 Cr | ₹11 Cr | ₹84 Cr |
What is the latest Total Non-Current Liabilities ratio of WANBURY ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹173 Cr |
| Mar2024 | ₹99 Cr |
| Mar2023 | ₹11 Cr |
| Mar2022 | ₹11 Cr |
| Mar2021 | ₹84 Cr |
How is Total Non-Current Liabilities of WANBURY Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹173 Cr | 74.78 | |
| Mar2024 | ₹99 Cr | 815.56 | |
| Mar2023 | ₹11 Cr | 2.34 | |
| Mar2022 | ₹11 Cr | -87.49 | |
| Mar2021 | ₹84 Cr | - | |
Compare Total Non-Current Liabilities of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹866.6 Cr | 1.2% | -2.5% | 18.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹430,825.0 Cr | -1.6% | 5.7% | 7.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,535.0 Cr | -4.2% | -1.4% | 9.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹145,733.0 Cr | -2.8% | 5.7% | 39.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,094.0 Cr | -3.2% | 1.2% | 14.2% | Stock Analytics | |
| CIPLA | ₹103,513.0 Cr | -3.6% | -3.7% | -10.2% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | 1.2% |
-2.5% |
18.8% |
| SENSEX | -2.7% |
-9.1% |
2.6% |
You may also like the below Video Courses